

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/066,009

02/01/2002

Michelle Schaffer

P1869R1

09157 GENENTECH, INC. 1 DNA WAY

1 DNA WAY SOUTH SAN FRANCISCO, CA 94080



CONFIRMATION NO. 2130
FORMALITIES LETTER
OC0000000008158555

Date Mailed: 05/21/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

6.0

0300

Patent Docket P1869R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Michelle Schaffer et al

Serial No.: 10/066,009

Filed: February 1, 2002

For:

CRYSTALLIZATION OF IGF-1

Group Art Unit: Unassigned

Examiner: Unassigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

June 18, 2002

Ann Savelli

TRANSMITTAL LETTER

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- 1. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- 2. Certificate re: Sequence Listing
- 3. Substitute Computer-Readable Diskette (containing sequence listing)

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: June 18, 2002

Rv

Janet E. Hasak Reg. No. 28,616

Telephone No. (650) 225-1896

09157
PATENT TRADEMARK OFFICE